Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The comp...
Q1 2026
May 7, 2026
FY 2025
Mar 11, 2026
Q4 2025
Q3 2025
Nov 5, 2025
Q2 2025
Aug 5, 2025